Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|February 22, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-02-2016
- Volume 11
- Issue 3
Patheon Signs Strategic Agreement with Grünenthal
Author(s)Pharmaceutical Technology Editors
Patheon will assist in the development of INTAC, a technology designed to reduce the abuse of controlled substances.
Advertisement
On Feb. 22, 2016 Patheon announced it has signed a strategic agreement with Grünenthal, an international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s abuse deterrent formulation technology INTAC.
Patheon was selected to assist with the development of advanced INTAC based products including single-entity and fixed-dose combination solid oral dosage forms with immediate and modified release properties. INTAC is Grünenthal’s proprietary technology designed to reduce the potential for abuse of controlled substances.
INTAC is an abuse-deterrent formulation technology platform, used with several FDA-approved opioid products. As part of the agreement, Grünenthal has agreed to install specialized equipment in Patheon’s Cincinnati manufacturing site.
Source: Patheon
Articles in this issue
over 10 years ago
Small-Scale Modeling Boosts Downstream Developmentover 10 years ago
Technologies Expand Horizons of the Analytical Labover 10 years ago
Global Conflicts and CMO Impactsover 10 years ago
Hazardous Reagents for Higher Yieldsover 10 years ago
Mechanical Pipettes Have Ergonomic Designover 10 years ago
Benchtop Centrifuge Features Hybrid Rotorover 10 years ago
Cirrus Pharmaceuticals Announces Manufacturing for Clinical Trialsover 10 years ago
ICIG Acquires Sandoz Site in Germanyover 10 years ago
Recipharm Acquires Italian CDMOAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5